VAK-694 Biosimilar – Anti-Binetrakin mAb – Research Grade from ProteoGenix; catalogue PX-TA1911; research use only.
Know who made it. See the evidence. Buy through one marketplace.
VAK-694 Biosimilar is a monoclonal antibody (mAb) that targets the protein Binetrakin, a key component of the immune system. This biosimilar is a highly specific and potent therapeutic agent that has shown promising results in pre-clinical studies. In this article, we will discuss the structure, activity, and potential applications of VAK-694 Biosimilar as an antibody targeting Binetrakin.
VAK-694 Biosimilar is a recombinant humanized IgG1 monoclonal antibody. It is composed of two identical heavy chains and two identical light chains, each containing a variable and constant region. The variable regions of the antibody are responsible for binding to the target protein, Binetrakin, while the constant regions are responsible for effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
VAK-694 Biosimilar binds to Binetrakin with high affinity and specificity, preventing its interaction with its receptors and inhibiting its activity. Binetrakin is a cytokine that is involved in the regulation of immune responses, and its dysregulation has been linked to various autoimmune diseases and inflammatory disorders. By targeting Binetrakin, VAK-694 Biosimilar can modulate the immune response and potentially treat these diseases.
In pre-clinical studies, VAK-694 Biosimilar has shown potent inhibition of Binetrakin activity in vitro and in vivo. It has also demonstrated efficacy in animal models of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. Additionally, VAK-694 Biosimilar has been shown to have a favorable safety profile, with no significant adverse effects observed in animal studies.
Based on its mechanism of action and pre-clinical data, VAK-694 Biosimilar has the potential to be used in the treatment of various autoimmune diseases and inflammatory disorders. These include but are not limited to rheumatoid arthritis, systemic lupus erythematosus, psoriasis, and inflammatory bowel disease. Additionally, VAK-694 Biosimilar may also have potential applications in the treatment of cancer, as Binetrakin has been shown to play a role in tumor growth and metastasis.
One of the main advantages of VAK-694 Biosimilar is its specificity for Binetrakin, which minimizes the risk of off-target effects and reduces the potential for adverse reactions. This makes it a promising therapeutic option for patients who may not respond well to traditional treatments or experience significant side effects.
In conclusion, VAK-694 Biosimilar is a recombinant humanized monoclonal antibody that targets the protein Binetrakin. It has shown potent inhibition of Binetrakin activity and has demonstrated efficacy in pre-clinical studies of autoimmune diseases and inflammatory disorders. With its high specificity and favorable safety profile, VAK-694 Biosimilar has the potential to be a valuable therapeutic option for patients in need of targeted treatment for these conditions. Further clinical studies are needed to fully evaluate its potential in the treatment of various diseases and to bring this biosimilar to the market.
ProteoGenix catalogue number PX-TA1911. For research use only.
Target: VAK-694 Biosimilar – Anti-Binetrakin mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| VAK-694 Biosimilar – Anti-Binetrakin mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
